Which companies overlap with Fondation Ophtalmologique Adolphe de Rothschild's portfolio?

Top competitors by shared drug class: Hoffmann-La Roche, Allergan, Assistance Publique - Hôpitaux de Paris, Genentech, Inc., University of Missouri-Columbia.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fondation-ophtalmologique-adolphe-de-rothschild.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Fondation Ophtalmologique Adolphe de Rothschild — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fondation Ophtalmologique Adolphe de Rothschild pipeline: 2 marketed, 0 filed, 3 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 3 Phase 3 2 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Budesonide Nasal	Budesonide Nasal	marketed
injection of NMBA	injection of NMBA	marketed	Neuromuscular blocking agent	Nicotinic acetylcholine receptor at neuromuscular junction	Anesthesia
Ocrelizumab Injection [Ocrevus]	Ocrelizumab Injection [Ocrevus]	phase 3	CD20-targeting monoclonal antibody	CD20	Immunology / Neurology
immediate treatment with corticosteroids	immediate treatment with corticosteroids	phase 3	Corticosteroid	Glucocorticoid receptor	Ophthalmology / Immunology
addition of rituximab if recurrence	addition of rituximab if recurrence	phase 3

Therapeutic area mix

Anesthesia · 1
Immunology / Neurology · 1
Ophthalmology / Immunology · 1
Pulmonary/Respiratory · 1
Respiratory · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Hoffmann-La Roche · 2 shared drug classes
Allergan · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
Genentech, Inc. · 2 shared drug classes
University of Missouri-Columbia · 2 shared drug classes
Acrotech Biopharma Inc. · 1 shared drug class
AbbVie · 1 shared drug class
AM-Pharma · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fondation Ophtalmologique Adolphe de Rothschild:

Cite this brief

Drug Landscape (2026). Fondation Ophtalmologique Adolphe de Rothschild — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fondation-ophtalmologique-adolphe-de-rothschild. Accessed 2026-05-17.